BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10345160)

  • 1. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.
    Bucaneve G; Menichetti F; Del Favero A
    Pharmacoeconomics; 1999 Jan; 15(1):85-95. PubMed ID: 10345160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
    Menichetti F; Del Favero A; Bucaneve G; Aversa F; Fiorio M
    Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients.
    Dranitsaris G; Tran TM; McGeer A; Narine L
    Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer.
    Castagnola E; Paola D; Giacchino R; Rossi R; Viscoli C
    Support Care Cancer; 1998 Nov; 6(6):524-8. PubMed ID: 9833301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
    Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
    Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.
    Del Favero A; Menichetti F; Guerciolini R; Bucaneve G; Baldelli F; Aversa F; Terenzi A; Davis S; Pauluzzi S
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1126-9. PubMed ID: 2959198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
    Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
    Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study.
    Sipahi OR; Kahraman H; Erdem HA; Yetkin F; Kaya S; Demirdal T; Tunccan OG; Karasahin O; Oruc E; Cag Y; Kurtaran B; Ulug M; Kutlu M; Avci M; Oztoprak N; Arda B; Pullukcu H; Tasbakan M; Yamazhan T; Kandemir O; Dizbay M; Sipahi H; Ulusoy S
    Infection; 2019 Apr; 47(2):259-266. PubMed ID: 30498901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of teicoplanin in the treatment of febrile neutropenia.
    Menichetti F
    J Chemother; 2000 Nov; 12 Suppl 5():34-9. PubMed ID: 11131962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
    D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
    Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients.
    Cony-Makhoul P; Brossard G; Marit G; Pellegrin JL; Texier-Maugein J; Reiffers J
    Br J Haematol; 1990 Dec; 76 Suppl 2():35-40. PubMed ID: 2149050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
    Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
    Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.
    Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
    Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
    J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.